Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

791 Press Releases
DateTitleCompany
24 Jul 17 Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin®1 (bevacizumab) Pfizer Inc.,
Published by
Business Wire
20 Jul 17 Pfizer Completes License Agreement For The Exclusive Commercialization Rights In Europe For CRESEMBA (isavuconazole), A Novel Treatment For Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients Pfizer Inc.,
Published by
Business Wire
11 Jul 17 FDA Advisory Committee Votes in Favor of Pfizer’s MYLOTARG (gemtuzumab ozogamicin) for Acute Myeloid Leukemia Pfizer Inc.,
Published by
Business Wire
30 Jun 17 BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia Pfizer Inc.,
Published by
Business Wire
27 Jun 17 Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri Pfizer Inc.,
Published by
Business Wire
22 Jun 17 Pfizer Declares 32-Cent Third-Quarter 2017 Dividend Pfizer Inc.,
Published by
Business Wire
20 Jun 17 Pfizer Invites Public To View And Listen To Webcast Of August 1 Conference Call With Analysts Pfizer Inc.,
Published by
Business Wire
19 Jun 17 Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine Pfizer Inc.,
Published by
Business Wire
14 Jun 17 Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients Pfizer Inc.,
Published by
Business Wire
13 Jun 17 Nearly One in Four New and Expectant Parents Have Never Heard of Invasive Pneumococcal Disease According to a New Survey Pfizer Inc.,
Published by
Business Wire
13 Jun 17 Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab Pfizer Inc.,
Published by
Business Wire
06 Jun 17 Pfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin Cardiomyopathy Pfizer Inc.,
Published by
Business Wire
03 Jun 17 Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer Pfizer Inc.,
Published by
Business Wire
25 May 17 FDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Epogen®/Procrit® Across All Indications Pfizer Inc.,
Published by
Business Wire
17 May 17 Pfizer Invites Public to View and Listen to Webcast of June 9 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations Pfizer Inc.,
Published by
Business Wire
04 May 17 Robert C. Rickert Joins Pfizer as Chief Scientific Officer of Rinat to Lead Early Discovery Efforts in Immuno-Oncology Pfizer Inc.,
Published by
Business Wire
03 May 17 Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritis Pfizer Inc.,
Published by
Business Wire
27 Apr 17 Pfizer’s Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer Pfizer Inc.,
Published by
Business Wire
21 Apr 17 Pfizer Unveils ATLAS®, An Interactive, User-Friendly Website That Provides Global Antibiotic Resistance Surveillance Data Across 60 Countries Pfizer Inc.,
Published by
Business Wire
27 Mar 17 XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA) Pfizer Inc.,
Published by
Business Wire
22 Mar 17 Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts Pfizer Inc.,
Published by
Business Wire
24 Feb 17 Pfizer Prices $1,065,000,000 Debt Offering Pfizer Inc.,
Published by
Business Wire
28 Feb 17 FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review Merck and Pfizer,
Published by
PR Newswire
28 Feb 17 FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review EMD Serono and Pfizer,
Published by
PR Newswire
21 Apr 17 Pfizer Receives Positive CHMP Opinion for BESPONSA® (Inotuzumab Ozogamicin) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia Pfizer Inc.,
Published by
Business Wire
01 Mar 17 Pfizer Prices €4,000,000,000 Debt Offering Pfizer Inc.,
Published by
Business Wire
24 Apr 17 Pivotal Phase III Study Underscores Efficacy Of Zavicefta™ (ceftazidime-avibactam) For Treatment Of Hospital-Acquired Pneumonia, A Leading Cause Of Mortality In Hospitals Pfizer,
Published by
Business Wire
27 Mar 17 FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma Merck-Pfizer Alliance,
Published by
PharmiWeb.com
14 Mar 17 Pfizer Launches Zavicefta™ (ceftazidime-avibactam) in the U.K. and Germany, a New Antibiotic to Treat Complicated Infections Caused by Gram-Negative Bacteria Pfizer Inc.,
Published by
Business Wire
20 Apr 17 Pfizer Invites Public To Listen To Webcast Of April 27 Annual Meeting Of Shareholders Pfizer Inc.,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.